CHL Medical Partners

Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion.

Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

CareWell Urgent Care operates emergency health care centers in the New England area. Its approach to urgent care includes on-site labs, x-ray capabilities, and dispensing of common medications. CareWell Urgent Care is based in Tewksbury, Massachusetts.

Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England Baptist Hospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows.

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes. The company's approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). OpGen was established in 2002 by David Schwartz in Rockville, Maryland.

Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of the h-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes. The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs.

Ambra Health is a medical data and image management software-as-a-service company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation and improve collaborative care workflows by offering secure and easy access to medical images. It serves a diverse clientele, including major health systems and radiology practices, enabling them to streamline their operations and enhance patient care. Ambra Health's solutions focus on agility, interoperability, and user-friendly design, allowing organizations to adopt and integrate the technology effectively while improving business outcomes. The company aims to meet the evolving needs of the healthcare industry by delivering innovative medical image management solutions.

Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion.

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes. The company's approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). OpGen was established in 2002 by David Schwartz in Rockville, Maryland.

Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in the United States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in the United States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California.

North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

BIKAM Pharmaceuticals is a drug discovery company focused on the discovery and development of novel drugs for degenerative diseases. It discovers and develops pharmacologic chaperones for misfolded proteins within the retina that lead to serious retinal degenerative disease and blindness, including retinitis pigmentosa and dry age-related macular degeneration. BIKAM Pharmaceuticals was founded in 2007 and is based in Cambridge, Massachusetts.

Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes. The company's approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). OpGen was established in 2002 by David Schwartz in Rockville, Maryland.

Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for the right patient, at the right time, for the right price" so its customers can deliver the best patient care while reducing costs, and more easily meeting compliance demands. Only Millennium combines Just-In-Time Dispensing with electronic medication and treatment ordering, administration, documentation, and reporting. Millennium backs up the commitment with delivery timeliness and medication accuracy customer guarantees. Millennium is headquartered in Chicago, Illinois.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Spine Wave, Inc. is a medical device manufacturer based in Shelton, Connecticut, specializing in solutions for spinal disorders. Founded in 2001, the company develops and markets a range of innovative products, including expandable PEEK spacers and interbody devices for posterior surgery, as well as pivoting and lateral spacer systems. Their offerings also include the Leva PX expandable interbody device, the GraftMag Graft Delivery System for bone grafts, and various fixation products designed to address conditions such as degeneration, deformity, tumors, and trauma of the thoracolumbar spine. Additionally, Spine Wave provides anterior cervical plate systems for spinal fusion and cervical spacer systems for treating degenerative disc disease. The company distributes its products through a network of distributors, focusing on delivering efficient and effective surgical solutions for spine surgeons and their patients.

Ascend Health Corporation is a behavioural healthcare provider, offering a full range of inpatient and day hospital services to children, adolescents, adults and seniors. They focus on personal choice and specialised care. Their facilities provide high quality care by working closely to integrate their services with the healthcare system in each local community.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. Cantex is currently conducting two unique development programs with modified versions of two separate known chemical entities each of which addresses major unmet medical needs representing high-value market opportunities:

Spine Wave, Inc. is a medical device manufacturer based in Shelton, Connecticut, specializing in solutions for spinal disorders. Founded in 2001, the company develops and markets a range of innovative products, including expandable PEEK spacers and interbody devices for posterior surgery, as well as pivoting and lateral spacer systems. Their offerings also include the Leva PX expandable interbody device, the GraftMag Graft Delivery System for bone grafts, and various fixation products designed to address conditions such as degeneration, deformity, tumors, and trauma of the thoracolumbar spine. Additionally, Spine Wave provides anterior cervical plate systems for spinal fusion and cervical spacer systems for treating degenerative disc disease. The company distributes its products through a network of distributors, focusing on delivering efficient and effective surgical solutions for spine surgeons and their patients.

Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

GeneOhm Sciences designs, develops, and delivers nucleic acid-based diagnostic solutions. It focuses on serving the unmet diagnostic needs in a wide range of diseases including inherited disease, infectious disease and oncology. It is developing rapid, nucleic acid-based systems that will detect and identify infectious agents and genetic variations. GeneOhm Sciences is dedicated to offering laboratories and clinical scientists cutting-edge, FDA-approved, molecular based tests that can provide results in less than two hours. Established in San Diego, California in 2001, GeneOhm Sciences merged with Infectio Diagnostic, Inc. of Québec, Canada in 2004. The integrated company combines an extensive portfolio of proprietary technology, strong industry expertise and capabilities with an experienced and accomplished management team to lead the way. Most of GeneOhm’s development focus is on the applications electric current flowing through DNA as a means to detect genetic mutations. GeneOhm was recently acquired by the BD Pharmaceuticals group.

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Eunoe, Inc. is a San Francisco Bay-area medical device company focused on the treatment of neurological disorders through the management of cerebrospinal fluid.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

Protometrix develops integrated proteomics technologies to improve human health. Protometrix focuses on the production and investigation of the function and interaction of proteins in parallel using nanoscale technology and collection of information in an informatics database.

Molecular Staging, Inc., a life sciences tool company, develops technologies for the detection and measurement of proteins and nucleic acids. It provides technologies for proteomics, genomics, pharmacogenomics, and diagnostics applications. The company’s products and services include protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins; whole-genome amplification that allows DNA samples as resources, enabling researchers to return to them for new tests or confirmatory diagnoses; and multiplexed diagnostics that enable earlier detection of disease.

Lifespire was created in late 1999 through the merging of 2 companies: Vida Healthcare and inspiria.com. Vida Healthcare, formed in 1996, has worked with hundreds of oncology doctors, nurses and allied health professionals to improve cancer care. Lifespire Their vision is to improve care through shared knowledge. But what does that mean to you, the patient, and your circle of family and friends They serve? It means that They are giving you and the ones closest to you -- your circle of care -- a resource for gathering credible knowledge, support and understanding of your experience with cancer. Some of you may have known us when They were Vida Healthcare. In Their four years as Vida, They delivered clinical support and education services to over 4,000 people experiencing cancer. Now They're bringing that experience and understanding to you. They're doing this in partnership with companies committed to improving the treatment of cancer. And They're using Lifespire.com as Their forum for delivery.

RxCentric is an e-health business-to-business company linking physicians' drug information and education needs with a targeted, online.

ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.